Skip to main content
. 2020 Jul 10;15(7):e0235821. doi: 10.1371/journal.pone.0235821

Table 1. Characteristics of included studies for systematic literature review of tuberculosis and risk of cardiovascular disease and related mortality.

First Author Year Country Source of TB Data Enrolment Period People Diagnosed with TB Design Study Objective (page no.) Follow-up in years: mean / median (max) ROBINS-I Overall ROB
Bakari 2013 Tanzania Hospital 2009–2010 34 Case-control Identify factors (e.g., TB) associated with heart failure in people living with HIV with cardiac complaint (p. 1) N/A Serious
Blöndal 2013 Estonia TB Register 2002–2009 2,449 Cohort Overall and cause-specific mortality among people with TB and MDR-TB compared to the general population (p. 961) Mean = 5.3 (9 years)* Serious
Christensen 2014 Denmark TB Register 1977–2008 8,291 Cohort Long-term mortality in TB survivors compared with the general population (p. 406) Mean = 9.6 (32 years)** Serious
Chung 2014 Taiwan Administrative Data 1997–2010 10,168 Cohort Assess risk of ACS in people with TB compared to controls (p. 80) Not stated (13 years) Serious
Giral 2007 France Hospital Not Stated 147 Case-control Analysis of past TB in relation to carotid and femoral atherosclerosis (p. 151) Mean = 25; SD = 11 between TB diagnosis and sonography Serious
Hasanain 2018 Egypt Hospital 2016–2017 54 Case-control Assess LTBI prevalence among those with/without CAS and evaluate LTBI as predictor of CAS N/A Serious
Huaman 2017 United States Administrative Data 2008–2010 2,026 Cohort Assess whether TB increased the risk of AMI after adjusting for CVD risk factors (p. 1364) Not stated (1 year) Moderate
Huaman 2018 Peru Hospital 2015–2017 120 Case-control Assess association between LTBI and AMI (p. 887) N/A Serious
Ke 2015 Taiwan Administrative Data 2008–2010 6,911 Cohort Analyze CVD and other adverse outcomes after non-chest surgeries in people with pulmonary TB compared to people without TB (p. 2) Not stated (2 years) Moderate
Mathew 2006 Russia TB Register 2002–2003 1,916 Cohort Risk factors for death during TB treatment (p. 857) Median = 241 days (censored at death or TB treatment completion) Serious
Oh 2017 South Korea Not Stated 2010–2014 69,023 Cohort Assess incidence of cardiovascular events during TB treatment and if pyrazinamide adds to this risk (p. A199) Not stated (4 years) NI
Pettit 2017 International ART-CC Data Coordinating Centre 1996–2014 2,174 Cohort Assess the effect of TB (and other ADEs) on non-AIDS mortality risk (p. 2) Median = 5.18 (IQR: 2.28–9.42 years) Serious
Sheu 2010 Taiwan Administrative Data 2000–2003 2,283 Cohort Assess ischemic stroke risk among people with TB during a 3-year period after diagnosis compared control patients (p. 244) Not stated (3 years) Serious
Shuldiner 2016 Israel TB Register 2000–2010 3,201 Cohort Assess long-term mortality among TB survivors in Israel, compared to the general population (p. 43) Median = 5.9 (11 years) Critical
Wang 2017 Taiwan Administrative Data 2000–2010 14,350 Cohort Assess PAD risk in people with TB compared to controls (p. 1671). Mean = 5.82 (11 years)* Moderate
Wu 2014 Taiwan Administrative Data 2001 5,804 Cohort Assess ischemic stroke after contracting TB (p. 2) Not stated (3 years) Serious

ACS = acute coronary syndrome, ADE = AIDS defining event, AIDS = autoimmune deficiency syndrome, AMI = acute myocardial infarction, ART = antiretroviral therapy, ART-CC = Antiretroviral Therapy Cohort Collaboration, CAS = coronary artery stenosis, HIV = human immunodeficiency virus, MDR-TB = multi-drug resistant tuberculosis, NADE = non-AIDS defining event, NI = no information, PAD = peripheral arterial disease, ROBINS-I = Risk of Bias In Non-Randomized Studies of Interventions, ROB = risk of bias, TB = tuberculosis.

*average of means for each group

**average of medians for each group